@article {Calderon220144, author = {Ariel A. Calderon and Colin Dimond and David F. Choy and Rajita Pappu and Michele A. Grimbaldeston and Divya Mohan and Kian Fan Chung}, title = {Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD}, volume = {32}, number = {167}, elocation-id = {220144}, year = {2023}, doi = {10.1183/16000617.0144-2022}, publisher = {European Respiratory Society}, abstract = {Interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are alarmins that are released upon airway epithelial injury from insults such as viruses and cigarette smoke, and play critical roles in the activation of immune cell populations such as mast cells, eosinophils and group 2 innate lymphoid cells. Both cytokines were previously understood to primarily drive type 2 (T2) inflammation, but there is emerging evidence for a role for these alarmins to additionally mediate non-T2 inflammation, with recent clinical trial data in asthma and COPD cohorts with non-T2 inflammation providing support. Currently available treatments for both COPD and asthma provide symptomatic relief with disease control, improving lung function and reducing exacerbation rates; however, there still remains an unmet need for further improving lung function and reducing exacerbations, particularly for those not responsive to currently available treatments. The epithelial cytokines/alarmins are involved in exacerbations; biologics targeting TSLP and IL-33 have been shown to reduce exacerbations in moderate-to-severe asthma, either in a broad population or in specific subgroups, respectively. For COPD, while there is clinical evidence for IL-33 blockade impacting exacerbations in COPD, clinical data from anti-TSLP therapies is awaited. Clinical data to date support an acceptable safety profile for patients with airway diseases for both anti-IL-33 and anti-TSLP antibodies in development. We examine the roles of IL-33 and TSLP, their potential use as drug targets, and the evidence for target patient populations for COPD and asthma, together with ongoing and future trials focused on these targets.Therapies targeting the alarmins IL-33 and TSLP form the next frontier for airway diseases. In addition to their role in adaptive immunity, emerging clinical data indicate these alarmins modulate innate immunity to address unmet needs in COPD and asthma. https://bit.ly/3tD8VM5}, issn = {0905-9180}, URL = {https://err.ersjournals.com/content/32/167/220144}, eprint = {https://err.ersjournals.com/content/32/167/220144.full.pdf}, journal = {European Respiratory Review} }